{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:27:29Z","timestamp":1789511249559,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["anesthesiology.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anesthesiology Clinics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.anclin.2017.01.021","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T05:33:50Z","timestamp":1494999230000},"page":"327-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacology of Octreotide"],"prefix":"10.1016","volume":"35","author":[{"given":"Reza M.","family":"Borna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Jahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Kmiecik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken F.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anclin.2017.01.021_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpainsymman.2010.05.002","article-title":"Therapeutic reviews: octreotide","volume":"40","author":"Wilcock","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.anclin.2017.01.021_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jclinane.2010.12.009","article-title":"Carcinoid syndrome and perioperative anesthetic considerations","volume":"23","author":"Mancuso","year":"2011","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.anclin.2017.01.021_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00001503-200306000-00017","article-title":"Carcinoid tumor and carcinoid syndrome","volume":"16","author":"Dierdorf","year":"2003","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.anclin.2017.01.021_bib4","series-title":"Sandostatin, Octreotide acetate injection; Prescribing Information","year":"2012"},{"issue":"6","key":"10.1016\/j.anclin.2017.01.021_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anclin.2017.01.021_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMra0901512","article-title":"Management of varices and variceal hemorrhage in cirrhosis","volume":"362","author":"Garcia-Tsao","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.021_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.critrevonc.2011.12.006","article-title":"Octreotide for malignant bowel obstruction: twenty years after","volume":"83","author":"Mercadante","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.021_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","article-title":"Role of Octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial","volume":"19","author":"Ripamonti","year":"2000","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.anclin.2017.01.021_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0885-3924(94)90144-9","article-title":"Subcutaneous octreotide in the treatment of pain in advanced cancer patients","volume":"9","author":"De Conno","year":"1994","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.021_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/00365520510024043","article-title":"Octreotide in the treatment of refractory ascites of cirrhosis","volume":"41","author":"Kalambokis","year":"2006","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.anclin.2017.01.021_bib11","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s10620-008-0566-6","article-title":"The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis","volume":"54","author":"Zhou","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.anclin.2017.01.021_bib12","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.transproceed.2015.07.036","article-title":"Effects of continuous octreotide infusion on intraoperative transfusion requirements during orthotopic liver transplantation","volume":"47","author":"Byram","year":"2015","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.021_bib13","first-page":"307","article-title":"Postoperative chylothorax: is octreotide a valid therapy?","volume":"3","author":"Owais","year":"2015","journal-title":"J\u00a0Case Rep Stud"},{"key":"10.1016\/j.anclin.2017.01.021_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","article-title":"Development of effective prophylaxis against intraoperative carcinoid crisis","volume":"32","author":"Woltering","year":"2016","journal-title":"J\u00a0Clin Anesth"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.021_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/0974-5009.165537","article-title":"Carcinoid tumors: challenges and considerations during anesthetic management","volume":"V42","author":"Bajwa","year":"2015","journal-title":"J\u00a0Scientific Soc"},{"key":"10.1016\/j.anclin.2017.01.021_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejso.2007.07.202","article-title":"Carcinoid syndrome","volume":"34","author":"Bendelow","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.anclin.2017.01.021_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004311-199703540-00009","article-title":"Anesthesia for patients with carcinoid syndrome","volume":"35","author":"Vaughan","year":"1997","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.anclin.2017.01.021_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/BF03017444","article-title":"Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide","volume":"49","author":"Orbach-Zinger","year":"2002","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.anclin.2017.01.021_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/bja\/aeh135","article-title":"Remifentanil and anaesthesia for carcinoid syndrome","volume":"92","author":"Farling","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.anclin.2017.01.021_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/2141-9248.122044","article-title":"Dexmedetomidine: an adjuvant making large inroads into clinical practice","volume":"3","author":"Bajwa","year":"2013","journal-title":"Ann Med Health Sci Res"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.021_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.surg.2015.05.036","article-title":"Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis","volume":"159","author":"Condron","year":"2015","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.anclin.2017.01.021_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J\u00a0Surg Oncol"}],"container-title":["Anesthesiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T19:29:49Z","timestamp":1535830189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1932227517300265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1932227517300265"],"URL":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.021","relation":{},"ISSN":["1932-2275"],"issn-type":[{"value":"1932-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of Octreotide","name":"articletitle","label":"Article Title"},{"value":"Anesthesiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}